Skip to content
Moehs Iberica logo — Active ingredients for pharmaceutical market

Moehs Iberica

Active ingredients for pharmaceutical market

Founded 1962 Spain Spain 215 employees Manufacturing, Pharmaceutical

General Information

Company Name Moehs Iberica
Founded Year 1962
Location Spain Spain
Employees 215
Industries Manufacturing, Pharmaceutical
Social

BounceWatch is an independent company data service, not affiliated with Moehs Iberica. To contact Moehs Iberica, visit moehs.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Moehs Iberica compare?

A PDF of Moehs Iberica and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Moehs Iberica soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Moehs Iberica

Moehs Iberica is a seasoned player in the manufacturing of active pharmaceutical and veterinary ingredients, agrochemicals, nutraceutical, and cosmetic ingredients. With a strong emphasis on quality and safety standards, including GMP's and ICH, the company's products are approved by the FDA and TGA. Boasting a rich tradition and experience since its establishment in 1962, Moehs Group has carved a global footprint, selling over 75 products in more than 90 countries and registering over 80 DMF's of different API's in more than 30 countries. As a subsidiary of American Chemical Corporation PMC Global Inc., Moehs Iberica, S.L. oversees the operations of several manufacturing plants, including Moehs Catalana, Moehs Cantabra, Moehs BCN, Coprima, Benechim, Norchim, and Chemische Fabrik Berg. With a focus on the manufacturing and pharmaceutical industries, the company is headquartered in Spain. Currently, there is no publicly available information regarding its last investment or the involved investors.

Business keywords: pharmaceutical manufacturing, active pharmaceutical ingredients, API production, FDA approved, GMP standards, global distribution, chemical manufacturing, nutraceuticals, cosmetic ingredients, agrochemicals, veterinary pharmaceuticals, quality standards, CMO services, drug development, international market presence

No funding data available for Moehs Iberica yet.

Moehs Iberica Alternatives & Competitors

View All Alternatives
Moehs Iberica vs

Where Opportunity Becomes Reality

1467 employees
Manufacturing, Pharmaceutical
Moehs Iberica vs

An Indian Pharmaceutical Company well know for API

178 employees
Manufacturing, Pharmaceutical
Moehs Iberica vs

Köklü Geçmişimizden, Sağlığın Geleceğine...

385 employees
Biotechnology, Health and Wellness

FAQ About Moehs Iberica

Active ingredients for pharmaceutical market
Moehs Iberica was founded in 1962.
Moehs Iberica is headquartered in Spain.
Moehs Iberica operates in Manufacturing and Pharmaceutical. Its work centres on pharmaceutical manufacturing, active pharmaceutical ingredients, API production and FDA approved.
Moehs Iberica has approximately 215 employees.
Top alternatives and competitors to Moehs Iberica include Neuland Laboratories Limited, Mac-Chem Products India Pvt. Ltd., Gensenta İlaç, Archimica S.p.A, Avra Laboratories Pvt Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Moehs Iberica and Neuland Laboratories Limited are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Moehs Iberica, https://bouncewatch.com/company/moehs-iberica, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout